Global Exporter & Bulk Supplier of Gemlieva 200 mg Injection

🌍 Introduction

Are you looking for a trusted, globally compliant exporter of Gemlieva 200 mg Injection? At Ernest Oncology (a division of Ernest Pharmaceutical Pvt. Ltd.), we specialize in the secure, efficient, and compliant distribution of critical oncology formulations. We supply Gemcitabine 200 mg injections to hospitals, specialized oncology clinics, and pharmaceutical distributors across the USA, UK, Australia, and South Africa.

🔬 1. Product Overview: Gemlieva 200 mg Injection

Gemlieva 200 mg Injection contains Gemcitabine, a nucleoside analog and potent antimetabolite used in the treatment of various solid tumors.

• Composition: Gemcitabine USP 200 mg

• Therapeutic Class: Antineoplastic / Antimetabolite

• Formulation Type: Lyophilized powder for reconstitution (Sterile IV Infusion)

• Storage Temperature: Store below 25°C. Do not refrigerate or freeze after reconstitution (as per clinical guidelines).

⚙️ 2. Mechanism of Action

Gemlieva functions by disrupting the life cycle of cancer cells through targeted genetic interference:

• DNA Synthesis Inhibition: As a pyrimidine antimetabolite, Gemcitabine replaces the building blocks (cytidine) in the DNA strand during replication.

• Masked Chain Termination: Once incorporated, it allows only one additional nucleotide to be added before completely blocking further DNA synthesis, essentially "locking" the cancer cell's ability to divide.

• Apoptosis: The cell recognizes the irreparable DNA damage and undergoes programmed cell death (apoptosis).

🏥 3. Therapeutic Indications

Gemlieva 200 mg Injection is widely used for:

• Pancreatic Cancer: First-line treatment for patients with locally advanced or metastatic adenocarcinoma.

• Non-Small Cell Lung Cancer (NSCLC): Often used in combination with Cisplatin.

• Breast Cancer: Used in combination with Paclitaxel after the failure of prior chemotherapy.

• Ovarian Cancer: Used in combination with Carboplatin for advanced stages.

• Bladder Cancer: Prescribed for advanced or metastatic urothelial cancer.

⚠️ 4. Administration & Safety Guidelines

• Route: Exclusively for Intravenous (IV) Infusion.

• Monitoring: Regular monitoring of liver (ALT/AST) and kidney function, as well as complete blood counts (CBC), is required to manage myelosuppression.

• Side Effects: Common side effects include nausea, fatigue, low blood counts (anemia, leucopenia), and transient skin rashes.